Jerome Pfund decreased its stake in Neurocrine Biosciences (NBIX) by 20.67% based on its latest 2016Q3 regulatory filing with the SEC. Sectoral Asset Management Inc sold 209,227 shares as the company’s stock rose 11.81% with the market. The hedge fund run by Jerome Pfund held 802,979 shares of the health care company at the end of 2016Q3, valued at $40.66M, down from 1.01 million at the end of the previous reported quarter. Sectoral Asset Management Inc who had been investing in Neurocrine Biosciences for a number of months, seems to be less bullish one the $3.47 billion market cap company. The stock is down 1.10% or $0.47 after the negative news, hitting $42.14 per share. About 147,127 shares traded hands. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has declined 16.76% since June 7, 2016 and is downtrending. It has underperformed by 24.18% the S&P500.
Sectoral Asset Management Inc, which manages about $3.30 billion and $1.02B US Long portfolio, upped its stake in Collegium Pharmaceutical by 411,445 shares to 705,845 shares, valued at $13.60 million in 2016Q3, according to the filing. It also increased its holding in Avexis Inc by 120,843 shares in the quarter, for a total of 146,515 shares, and has risen its stake in Intuitive Surgical Inc (NASDAQ:ISRG).
Founded in 2000, Sectoral Asset Management has as managers Michael Sjostrom and Jerome fund. The firm’s main focus is in the healthcare sector. Sectoral is involved in the domain of health management, genome, biotech, and is not afraid to get involved in emerging markets or small caps. Sectoral Asset Management Inc is a Quebec, Canada-based hedge fund that was founded by Jerome Pfund And Michael Sjostrom. It had more than $3.30 billion assets under management in November, 2014. Taken from Sectoral Asset Management latest Adv, the fund reported to have 22 full and part-time employees. Among which 12 performing investment advisory and research functions. The hedge fund had between 11-25 clients.
Insitutional Activity: The institutional sentiment increased to 1.09 in 2016 Q3. Its up 0.20, from 0.89 in 2016Q2. The ratio increased, as 25 funds sold all NBIX shares owned while 79 reduced positions. 39 funds bought stakes while 74 increased positions. They now own 84.11 million shares or 1.16% more from 83.14 million shares in 2016Q2. Rothschild Asset Management holds 0.01% or 7,775 shares in its portfolio. Mutual Of America Cap Mgmt Limited Liability has invested 0.07% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Perceptive Advsr Limited Company has 8.09% invested in the company for 2.48M shares. Moreover, Sivik Glob Health Ltd Liability Company has 0.4% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 15,600 shares. Ameriprise Finance Inc holds 0% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 61,963 shares. Cap Ww, a California-based fund reported 1.48M shares. Pnc Fincl Svcs Grp Inc holds 0% or 20,990 shares in its portfolio. Deutsche Bancshares Ag accumulated 1.02 million shares or 0.04% of the stock. Thrivent Fin For Lutherans reported 253,353 shares or 0.06% of all its holdings. Moreover, Ent Serv has 0.01% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 215 shares. Moreover, Allianz Asset Management Ag has 0.01% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 228,745 shares. American Interest has 0% invested in the company for 2,031 shares. Artal Gru Sa holds 0.1% or 100,000 shares in its portfolio. Canada Pension Plan Investment Board owns 9,300 shares or 0% of their US portfolio. Ridgeworth Capital Limited Liability accumulated 0.01% or 11,970 shares.
Insider Transactions: Since August 8, 2016, the stock had 0 buys, and 4 selling transactions for $2.62 million net activity. The insider OBrien Christopher Flint sold $609,125. $242,700 worth of shares were sold by Nevinny Corinne H on Monday, August 8. $450,000 worth of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares were sold by Lloyd-Smith Malcolm.
Analysts await Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to report earnings on February, 9. They expect $-0.58 EPS, down 70.59% or $0.24 from last year’s $-0.34 per share. After $-0.43 actual EPS reported by Neurocrine Biosciences, Inc. for the previous quarter, Wall Street now forecasts 34.88% negative EPS growth.
More notable recent Neurocrine Biosciences, Inc. (NASDAQ:NBIX) news were published by: Finance.Yahoo.com which released: “Neurocrine Biosciences Announces the Appointment of David-Alexandre Gros M.D …” on January 06, 2017, also Prnewswire.com with their article: “Neurocrine Biosciences to Present at the 35th Annual J.P. Morgan Healthcare …” published on December 21, 2016, Prnewswire.com published: “Neurocrine Biosciences Announces Chief Financial Officer Timothy P. Coughlin …” on December 21, 2016. More interesting news about Neurocrine Biosciences, Inc. (NASDAQ:NBIX) were released by: Prnewswire.com and their article: “Neurocrine Biosciences Reports Third Quarter 2016 Results” published on November 02, 2016 as well as Prnewswire.com‘s news article titled: “Neurocrine Announces FDA Conditional Acceptance of Proprietary Name INGREZZA …” with publication date: August 31, 2016.
According to Zacks Investment Research, “Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company’s neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity and diabetes.”
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Ratings Coverage
Out of 8 analysts covering Neurocrine Biosci (NASDAQ:NBIX), 7 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 88% are positive. Neurocrine Biosci has been the topic of 8 analyst reports since August 18, 2015 according to StockzIntelligence Inc. Jefferies reinitiated the shares of NBIX in a report on Tuesday, August 18 with “Buy” rating. Oppenheimer initiated the shares of NBIX in a report on Tuesday, November 22 with “Perform” rating. On Tuesday, October 18 the stock rating was initiated by Needham with “Buy”. On Wednesday, June 29 the stock rating was initiated by H.C. Wainwright with “Buy”. As per Thursday, November 3, the company rating was initiated by Deutsche Bank. BMO Capital Markets initiated the stock with “Outperform” rating in Thursday, April 7 report. The rating was maintained by Piper Jaffray on Thursday, October 8 with “Overweight”. The rating was maintained by Leerink Swann with “Outperform” on Monday, October 12.
NBIX Company Profile
Neurocrine Biosciences, Inc., incorporated on March 20, 1996, is engaged in the development of pharmaceutical products focused on neurological and endocrine diseases and disorders. The Company’s two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc. (AbbVie), and NBI-98854 (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. The Firm focuses on developing NBI-640756 against Essential tremor. The Company’s research and development focuses on addressing diseases and disorders of the central nervous and endocrine systems, which include therapeutic categories ranging from hypothalamic-pituitary-adrenal (HPA) disorders to stress-related disorders and neurological/neuropsychiatric diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.